|Bid||115.50 x 800|
|Ask||118.50 x 900|
|Day's Range||111.53 - 118.08|
|52 Week Range||74.31 - 181.07|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 04, 2021 - Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||178.30|
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate?
Cathie Wood has gained notoriety from making some seemingly outlandish calls on stocks and for being right. One of her less controversial projections is around preventative cancer screening. Specifically, she and her team believe liquid-biopsy screening for cancer could grow to a $150 billion market as the cost of tests drop.
Thank you for standing by, and welcome to the Guardant Health Q1 2021 Earnings Call. Earlier today, Guardant Health released financial results for the quarter ended March 31, 2021. Joining me today from Guardant is Helmy Eltoukhy, Chief Executive Officer; AmirAli Talasaz, President; and Mike Bell, Chief Financial Officer.